Drugs / OT-C001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07044050 | Jun 2025 → Sep 2026 overdue | diffuse large B-cell lymphoma | Emercell SAS | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OT-C001 | “OT-C001 will be administered by IV infusion weekly for at least 3 doses.” NCT07044050 ↗ |
| Modality | Cell therapy | “allogenic natural killer cells” NCT07044050 ↗ |
| Route | Intravenous | “OT-C001 will be administered by IV infusion weekly for at least 3 doses.” NCT07044050 ↗ |